Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.4.21.26 - prolyl oligopeptidase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acromegaly
Fibroblast activation protein is a GH target: A prospective study of patients with acromegaly before and after treatment.
Acute Coronary Syndrome
Circulating concentrations of fibroblast activation protein ? in apparently healthy individuals and patients with acute coronary syndrome as assessed by sandwich ELISA.
Acute Lung Injury
Effects of a natural prolyl oligopeptidase inhibitor, rosmarinic acid, on lipopolysaccharide-induced acute lung injury in mice.
The protective role of prolyl oligopeptidase (POP) inhibition in acute lung injury induced by intestinal ischemia-reperfusion.
Adenocarcinoma
Blockade of fibroblast activation protein in combination with radiation treatment in murine models of pancreatic adenocarcinoma.
Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance.
Fibroblast activation protein and its prognostic significance in correlation with vascular endothelial growth factor in pancreatic adenocarcinoma.
Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma.
Fibroblast activation protein augments progression and metastasis of pancreatic ductal adenocarcinoma.
Noncontrast Magnetic Resonance Radiomics and Multilayer Perceptron Network Classifier: An approach for Predicting Fibroblast Activation Protein Expression in Patients With Pancreatic Ductal Adenocarcinoma.
Alzheimer Disease
Brain prolyl oligopeptidase activity is associated with neuronal damage rather than beta-amyloid accumulation.
Cholinesterase and Prolyl Oligopeptidase Inhibitory Activities of Alkaloids from Argemone platyceras (Papaveraceae).
Comparison of proline endopeptidase activity in brain tissue from normal cases and cases with Alzheimer's disease, Lewy body dementia, Parkinson's disease and Huntington's disease.
In silico methods to identify meat-derived prolyl endopeptidase inhibitors.
Plant phenolics as prolyl endopeptidase inhibitors.
Prolyl oligopeptidase colocalizes with ?-synuclein, ?-amyloid, tau protein and astroglia in the post-mortem brain samples with Parkinson's and Alzheimer's diseases.
Quantitative structure-activity relationship of prolyl oligopeptidase inhibitory peptides derived from beta-casein using simple amino acid descriptors.
S 17092-1, a highly potent, specific and cell permeant inhibitor of human proline endopeptidase.
Amnesia
Inhibition of prolyl oligopeptidase by Fmoc-aminoacylpyrrolidine-2-nitriles.
Structure-function properties of prolyl oligopeptidase family enzymes.
The prolyl oligopeptidase family.
Unclosed beta-propellers display stable structures: implications for substrate access to the active site of prolyl oligopeptidase.
[Changes in proline-specific peptidase activity in experimental model of retrograde amnesia]
Arthritis
Circulating concentrations of fibroblast activation protein ? in apparently healthy individuals and patients with acute coronary syndrome as assessed by sandwich ELISA.
Deletion of fibroblast activation protein provides atheroprotection.
Fibroblast activation protein is induced by inflammation and degrades type I collagen in thin-cap fibroatheromata.
Selective Homogeneous Assay for Circulating Endopeptidase Fibroblast Activation Protein (FAP).
Stromal cell markers are differentially expressed in the synovial tissue of patients with early arthritis.
Arthritis, Experimental
Imaging fibroblast activation protein to monitor therapeutic effects of neutralizing interleukin-22 in collagen-induced arthritis.
Arthritis, Rheumatoid
Circulating fibroblast activation protein and dipeptidyl peptidase 4 in rheumatoid arthritis and systemic sclerosis.
Deletion of fibroblast activation protein provides atheroprotection.
Inhibition of fibroblast activation protein and dipeptidyl peptidase IV increases cartilage invasion by rheumatoid arthritis synovial fibroblasts.
Targeting of fibroblast activation protein in rheumatoid arthritis patients: imaging and ex vivo photodynamic therapy.
Astrocytoma
Fibroblast Activation Protein in Remodeling Tissues.
Atherosclerosis
The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis.
Brain Diseases
Mechanism of Action of Prolyl Oligopeptidase (PREP) in Degenerative Brain Diseases: Has Peptidase Activity Only a Modulatory Role on the Interactions of PREP with Proteins?
Brain Ischemia
ZTTA, a postproline cleaving enzyme inhibitor, improves cerebral ischemia-induced deficits in a three-panel runway task in rats.
Breast Neoplasms
A potent immunotoxin targeting fibroblast activation protein for treatment of breast cancer in mice.
Anti-tumor effects of DNA vaccine targeting human fibroblast activation protein ? by producing specific immune responses and altering tumor microenvironment in the 4T1 murine breast cancer model.
Co-Stimulatory Bispecific Antibodies Induce Enhanced T Cell Activation and Tumor Cell Killing in Breast Cancer Models.
Cyclophosphamide enhances anti-tumor effects of a fibroblast activation protein ?-based DNA vaccine in tumor-bearing mice with murine breast carcinoma.
Expression and targeting of human fibroblast activation protein in a human skin/severe combined immunodeficient mouse breast cancer xenograft model.
FAP Delineates Heterogeneous and Functionally Divergent Stromal Cells in Immune-Excluded Breast Tumors.
Fibroblast activation protein expression by stromal cells and tumor-associated macrophages in human breast cancer.
Immunization of stromal cell targeting fibroblast activation protein providing immunotherapy to breast cancer mouse model.
Improvement of anti-tumor immunity of fibroblast activation protein ? based vaccines by combination with cyclophosphamide in a murine model of breast cancer.
Molecular characterization of human breast tumor vascular cells.
The prolyl oligopeptidase inhibitor SUAM-14746 attenuates the proliferation of human breast cancer cell lines in vitro.
Tumor elastography and its association with cell-free tumor DNA in the plasma of breast tumor patients: a pilot study.
Carcinogenesis
Expression of the Peptidase "Fibroblast Activation Protein" on Decidual Stromal Cells Facilitating Tissue Remodeling.
On the edge of validation--cancer protease fibroblast activation protein.
Peptide substrate profiling defines fibroblast activation protein as an endopeptidase of strict Gly(2)-Pro(1)-cleaving specificity.
Carcinoma
Detecting fibroblast activation proteins in lymphoma using 68Ga-FAPI PET/CT.
Downregulation of FAP suppresses cell proliferation and metastasis through PTEN/PI3K/AKT and Ras-ERK signaling in oral squamous cell carcinoma.
Enhancement of fibroblast activation protein ?-based vaccines and adenovirus boost immunity by cyclophosphamide through inhibiting IL-10 expression in 4T1 tumor bearing mice.
Evaluation of the circulating level of fibroblast activation protein ? for diagnosis of esophageal squamous cell carcinoma.
Fibroblast Activation Protein (FAP) Overexpression Induces Epithelial-Mesenchymal Transition (EMT) in Oral Squamous Cell Carcinoma by Down-Regulating Dipeptidyl Peptidase 9 (DPP9).
Fibroblast activation protein and its prognostic significance in correlation with vascular endothelial growth factor in pancreatic adenocarcinoma.
Fibroblast activation protein predicts prognosis in clear cell renal cell carcinoma.
Human antibody derivatives against the fibroblast activation protein for tumor stroma targeting of carcinomas.
Identification of inhibitory scFv antibodies targeting fibroblast activation protein utilizing phage display functional screens.
Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase.
Integral membrane protease fibroblast activation protein sensitizes fibrosarcoma to chemotherapy and alters cell death mechanisms.
Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy.
Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)-activated prodrug in murine xenograft models of human cancer.
Photodynamic molecular beacon triggered by fibroblast activation protein on cancer-associated fibroblasts for diagnosis and treatment of epithelial cancers.
Photoimmunotherapy for cancer-associated fibroblasts targeting fibroblast activation protein in human esophageal squamous cell carcinoma.
Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients.
Species-crossreactive scFv against the tumor stroma marker "fibroblast activation protein" selected by phage display from an immunized FAP-/- knock-out mouse.
Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity - initial experience and comparison to [18F]FDG PET/CT and MRI.
The coexpression of fibroblast activation protein (FAP) and basal-type markers (CK 5/6 and CD44) predicts prognosis in high-grade invasive urothelial carcinoma of the bladder.
The Expression of FAP in Hepatocellular Carcinoma Cells is Induced by Hypoxia and Correlates with Poor Clinical Outcomes.
The Expression of Fibroblast Activation Protein in Clear Cell Renal Cell Carcinomas Is Associated with Synchronous Lymph Node Metastases.
Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells.
Whole Exome Sequencing Reveals a Novel Damaging Mutation in Human Fibroblast Activation Protein in a Family with Esophageal Squamous Cell Carcinoma.
Carcinoma, Hepatocellular
Increased expression of CCN2, epithelial membrane antigen, and fibroblast activation protein in hepatocellular carcinoma with fibrous stroma showing aggressive behavior.
Neuropeptide Y is a physiological substrate of fibroblast activation protein: Enzyme kinetics in blood plasma and expression of Y2R and Y5R in human liver cirrhosis and hepatocellular carcinoma.
[Expression of fibroblast activation protein in HBV related hepatocellular carcinoma].
Carcinoma, Non-Small-Cell Lung
Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer.
Carcinoma, Ovarian Epithelial
Fibroblast activation protein regulates tumor-associated fibroblasts and epithelial ovarian cancer cells.
Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer.
Carcinoma, Renal Cell
Fibroblast activation protein predicts prognosis in clear cell renal cell carcinoma.
The Expression of Fibroblast Activation Protein in Clear Cell Renal Cell Carcinomas Is Associated with Synchronous Lymph Node Metastases.
Carcinoma, Squamous Cell
Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity - initial experience and comparison to [18F]FDG PET/CT and MRI.
Cardiotoxicity
Fibroblast Activation Protein ? Activated Tripeptide Bufadienolide Antitumor Prodrug with Reduced Cardiotoxicity.
Cardiovascular Diseases
Relationship Between Cardiac Fibroblast Activation Protein Activity by Positron Emission Tomography and Cardiovascular Disease.
Celiac Disease
Generation of food-grade recombinant Lactobacillus casei delivering Myxococcus xanthus prolyl endopeptidase.
Highly efficient gluten degradation with a newly identified prolyl endoprotease: implications for celiac disease.
The Glutenase ALV003 Attenuates Gluten-Induced Mucosal Injury in Patients with Celiac Disease.
The human digestive tract has proteases capable of gluten hydrolysis.
Chagas Disease
Trypanosoma cruzi 80 kDa prolyl oligopeptidase (Tc80) as a novel immunogen for Chagas disease vaccine.
Cholangiocarcinoma
Expression of fibroblast activation protein and the clinicopathological relevance in distal cholangiocarcinoma.
Colonic Neoplasms
Clinical implications of fibroblast activation protein in patients with colon cancer.
High intratumoral expression of fibroblast activation protein (FAP) in colon cancer is associated with poorer patient prognosis.
Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model.
Protumorigenic effects of Snail-expression fibroblasts on colon cancer cells.
Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer.
Colorectal Neoplasms
Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts.
Colorectal cancer cells activate adjacent fibroblasts resulting in FGF1/FGFR3 signaling and increased invasion.
Comparisons of cancer-associated fibroblasts in the intratumoral stroma and invasive front in colorectal cancer.
Distribution of prolyl oligopeptidase in human peripheral tissues and in ovarian and colorectal tumors.
High intratumoral expression of fibroblast activation protein (FAP) in colon cancer is associated with poorer patient prognosis.
Phase II Trial of Single Agent Val-boroPro (Talabostat) Inhibiting Fibroblast Activation Protein in Patients with Metastatic Colorectal Cancer.
Predictive values of FAP and HGF for tumor angiogenesis and metastasis in colorectal cancer.
[Expression and clinical significance of fibroblast activation protein in colorectal carcinoma tissue].
Corneal Neovascularization
Expression of MMP, HPSE, and FAP in stroma promoted corneal neovascularization induced by different etiological factors.
[Relationship between corneal neovascularization and various relevant biological factors in surrounding cornea stroma of rats]
Coronary Artery Disease
Incidental Detection of Ischemic Myocardium on 68 Ga-FAPI PET/CT.
Coronary Disease
Circulating fibroblast activation protein activity and antigen levels correlate strongly when measured in liver disease and coronary heart disease.
Crohn Disease
Fibroblast activation protein expression in Crohn's disease strictures.
Inhibition of Fibroblast Activation Protein Restores a Balanced Extracellular Matrix and Reduces Fibrosis in Crohn's Disease Strictures Ex Vivo.
Dementia
Comparison of proline endopeptidase activity in brain tissue from normal cases and cases with Alzheimer's disease, Lewy body dementia, Parkinson's disease and Huntington's disease.
Deficiency of prolyl oligopeptidase in mice disturbs synaptic plasticity and reduces anxiety-like behaviour, body weight, and brain volume.
Diabetes Mellitus, Type 2
Crystal structures of human dipeptidyl peptidase IV in its apo and diprotin B-complexed forms.
FGF21 is an insulin-dependent postprandial hormone in adult humans.
Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity.
The prolyl oligopeptidase family.
Epilepsy
Spatiotemporal expression and inhibition of prolyl oligopeptidase contradict its involvement in key pathologic mechanisms of kainic acid-induced temporal lobe epilepsy in rats.
Epilepsy, Temporal Lobe
Spatiotemporal expression and inhibition of prolyl oligopeptidase contradict its involvement in key pathologic mechanisms of kainic acid-induced temporal lobe epilepsy in rats.
Esophageal Diseases
Evaluation of the circulating level of fibroblast activation protein ? for diagnosis of esophageal squamous cell carcinoma.
Esophageal Neoplasms
Fibroblast activation protein targeted near infrared photoimmunotherapy (NIR PIT) overcomes therapeutic resistance in human esophageal cancer.
Impact of Primary Staging with Fibroblast Activation Protein Specific Enzyme Inhibitor (FAPI)-PET/CT on Radio-Oncologic Treatment Planning of Patients with Esophageal Cancer.
Esophageal Squamous Cell Carcinoma
Evaluation of the circulating level of fibroblast activation protein ? for diagnosis of esophageal squamous cell carcinoma.
Photoimmunotherapy for cancer-associated fibroblasts targeting fibroblast activation protein in human esophageal squamous cell carcinoma.
Whole Exome Sequencing Reveals a Novel Damaging Mutation in Human Fibroblast Activation Protein in a Family with Esophageal Squamous Cell Carcinoma.
Fatty Liver
Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity.
Fibrosarcoma
Dataset on FAP-induced emergence of spontaneous metastases and on the preparation of activatable FAP-targeting immunoliposomes to detect the metastases.
Fibroblast activation protein increases metastatic potential of fibrosarcoma line HT1080 through upregulation of integrin-mediated signaling pathways.
Integral membrane protease fibroblast activation protein sensitizes fibrosarcoma to chemotherapy and alters cell death mechanisms.
Potential of activatable FAP-targeting immunoliposomes in intraoperative imaging of spontaneous metastases.
Genetic Diseases, Inborn
Molecular dynamics, crystallography and mutagenesis studies on the substrate gating mechanism of prolyl oligopeptidase.
Glioblastoma
Endothelial, pericyte and tumor cell expression in glioblastoma identifies fibroblast activation protein (FAP) as an excellent target for immunotherapy.
FAP-specific PET signaling shows a moderately positive correlation with relative CBV and no correlation with ADC in 13 IDH wildtype glioblastomas.
Fibroblast Activation Protein (FAP) specific PET for advanced target volume delineation in glioblastoma.
Fibroblast Activation Protein Expressing Mesenchymal Cells Promote Glioblastoma Angiogenesis.
Heterogeneity of molecular forms of dipeptidyl peptidase-IV and fibroblast activation protein in human glioblastomas.
Regulation of Fibroblast Activation Protein by Transforming Growth Factor Beta-1 in Glioblastoma Microenvironment.
Glioma
Dipeptidyl peptidase-IV inhibits glioma cell growth independent of its enzymatic activity.
Rational Design, Pharmacomodulation, and Synthesis of [68Ga]Ga-Alb-FAPtp-01, a Selective Tumor-Associated Fibroblast Activation Protein Tracer for PET Imaging of Glioma.
Granuloma
An improved noninfectious murine skin model of organized granulomatous inflammation.
Head and Neck Neoplasms
Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers.
Hematologic Neoplasms
Detecting fibroblast activation proteins in lymphoma using 68Ga-FAPI PET/CT.
Hepatitis C
Intrahepatic expression of collagen and fibroblast activation protein (FAP) in hepatitis C virus infection.
Intrahepatic expression of the hepatic stellate cell marker fibroblast activation protein correlates with the degree of fibrosis in hepatitis C virus infection.
Huntington Disease
Comparison of proline endopeptidase activity in brain tissue from normal cases and cases with Alzheimer's disease, Lewy body dementia, Parkinson's disease and Huntington's disease.
Decreased proline endopeptidase activity in the basal ganglia in Huntington's disease.
Prolyl oligopeptidase inhibition reduces PolyQ aggregation and improves cell viability in cellular model of Huntington's disease.
Hypersensitivity
Significant accumulations of cathepsin B and prolylendopeptidase in inflammatory focus of delayed-type hypersensitivity induced by Mycobacterium tuberculosis in mice.
Hypertension
Distribution of prolyl oligopeptidase in human peripheral tissues and body fluids.
Increased angiotensin II-induced hypertension and inflammatory cytokines in mice lacking angiotensin-converting enzyme N domain activity.
Idiopathic Pulmonary Fibrosis
Fibroblast activation protein: a serine protease expressed at the remodeling interface in idiopathic pulmonary fibrosis.
Loss of cells expressing fibroblast activation protein has variable effects in models of TGF-? and chronic bleomycin-induced fibrosis.
Immunoglobulin G4-Related Disease
Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging.
Fibroblast activation protein targeted PET/CT with 68Ga-FAPI for imaging IgG4-related disease: comparison to 18F-FDG PET/CT.
Infections
Identification of novel Trypanosoma cruzi prolyl oligopeptidase inhibitors by structure-based virtual screening.
Prolyl Oligopeptidase From Leishmania infantum: Biochemical Characterization and Involvement in Macrophage Infection.
Insulinoma
Evidence for pyroglutamyl peptidase I and prolyl endopeptidase activities in the rat insulinoma cell line RINm 5F: lack of relationship with TRH metabolism.
Ischemic Stroke
Acute Ischemic Stroke Severity, Progression, and Outcome Relate to Changes in Dipeptidyl Peptidase IV and Fibroblast Activation Protein Activity.
Incorporation of ?2-Plasmin Inhibitor into Fibrin Clots and Its Association with the Clinical Outcome of Acute Ischemic Stroke Patients.
Joint Diseases
Increased uptake of 68Ga-DOTA-FAPI-04 in bones and joints: metastases and beyond.
Kidney Neoplasms
Fibroblast activation protein predicts prognosis in clear cell renal cell carcinoma.
Leukemia
Intracellular activation and deactivation of tasidotin, an analog of dolastatin 15: correlation with cytotoxicity.
Leukemia, Myeloid, Acute
Expression and role of fibroblast activation protein ? in acute myeloid leukemia.
Prolyl oligopeptidase inhibitor suppresses the upregulation of ACSDKP in patients with acute myeloid leukemia.
Lewy Body Disease
Comparison of proline endopeptidase activity in brain tissue from normal cases and cases with Alzheimer's disease, Lewy body dementia, Parkinson's disease and Huntington's disease.
Liver Cirrhosis
Fibroblast activation protein in liver fibrosis.
Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity.
Neuropeptide Y is a physiological substrate of fibroblast activation protein: Enzyme kinetics in blood plasma and expression of Y2R and Y5R in human liver cirrhosis and hepatocellular carcinoma.
Liver Diseases
Circulating fibroblast activation protein activity and antigen levels correlate strongly when measured in liver disease and coronary heart disease.
Extraenzymatic functions of the dipeptidyl peptidase IV-related proteins DP8 and DP9 in cell adhesion, migration and apoptosis.
Fibroblast activation protein and chronic liver disease.
Immunoglobulin G4-Related Sclerosing Cholangitis Revealed by 68Ga-FAPI PET/MR.
Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity.
Liver Failure
The expression levels of prolyl oligopeptidase responds not only to neuroinflammation but also to systemic inflammation upon liver failure in rat models and cirrhotic patients.
Liver Neoplasms
Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [68Ga]Ga-FAPI-04 PET/CT versus MRI and [18F]-FDG PET/CT.
Lordosis
Decrease of sexual receptivity by prolylendopeptidase inhibitor in female rats.
Lung Diseases, Interstitial
Fibroblast Activation Protein specific PET/CT imaging in fibrotic interstitial lung diseases and lung cancer: a translational exploratory study.
Lung Neoplasms
Epidural adipose tissue-derived mesenchymal stem cell activation induced by lung cancer cells promotes malignancy and EMT of lung cancer.
Fibroblast Activation Protein specific PET/CT imaging in fibrotic interstitial lung diseases and lung cancer: a translational exploratory study.
Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer.
Lymphatic Metastasis
Fibroblast activation protein-positive fibroblasts promote tumor progression through secretion of CCL2 and interleukin-6 in esophageal squamous cell carcinoma.
The Expression of Fibroblast Activation Protein in Clear Cell Renal Cell Carcinomas Is Associated with Synchronous Lymph Node Metastases.
Malnutrition
Undernutrition during suckling does not change the specific or total activity of hypothalamic proline endopeptidase in adult rats.
Melanoma
Activation of the A2B adenosine receptor in B16 melanomas induces CXCL12 expression in FAP-positive tumor stromal cells, enhancing tumor progression.
Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma.
Melanoma, Experimental
Vaccine-induced CD8 T cells are redirected with peptide-MHC class I-IgG antibody fusion proteins to eliminate tumor cells in vivo.
Memory Disorders
Electrostatic effects and binding determinants in the catalysis of prolyl oligopeptidase. Site specific mutagenesis at the oxyanion binding site.
Prolyl Oligopeptidase: A Rising Star on the Stage of Neuroinflammation Research.
Substrate- and pH-dependent contribution of oxyanion binding site to the catalysis of prolyl oligopeptidase, a paradigm of the serine oligopeptidase family.
Substrate-dependent competency of the catalytic triad of prolyl oligopeptidase.
The noncatalytic beta-propeller domain of prolyl oligopeptidase enhances the catalytic capability of the peptidase domain.
Mesothelioma
Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trial.
Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1).
Mesothelioma, Malignant
Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1).
Monoclonal Gammopathy of Undetermined Significance
Rhu-Epo down-regulates pro-tumorigenic activity of cancer-associated fibroblasts in multiple myeloma.
Mouth Neoplasms
Genomewide mRNA profiling of esophageal squamous cell carcinoma for identification of cancer biomarkers.
Human telomerase reverse transcriptase (hTERT) promotes cancer invasion by modulating cathepsin D via early growth response (EGR)-1.
Multiple Myeloma
Fibroblast activation protein protects bortezomib-induced apoptosis in multiple myeloma cells through ?-catenin signaling pathway.
Multiple Myeloma Bone Marrow Mesenchymal Stromal Cells Inhibit CD8+ T Cell Function in a Process that May Implicate Fibroblast Activation Protein ?.
Multiple Sclerosis
Alteration of prolyl oligopeptidase and activated ?-2-macroglobulin in multiple sclerosis subtypes and in the clinically isolated syndrome.
The expression levels of prolyl oligopeptidase responds not only to neuroinflammation but also to systemic inflammation upon liver failure in rat models and cirrhotic patients.
Multiple Sclerosis, Relapsing-Remitting
Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis.
Multiple System Atrophy
Prolyl oligopeptidase inhibition reduces alpha-synuclein aggregation in a cellular model of multiple system atrophy.
Myocardial Infarction
Imaging of cardiac fibroblast activation in a patient after acute myocardial infarction using 68Ga-FAPI-04.
Molecular imaging of fibroblast activation protein after myocardial infarction using the novel radiotracer [68Ga]MHLL1.
Molecular imaging of fibroblast activity after myocardial infarction using a 68Ga-labelled fibroblast activation protein inhibitor FAPI-04.
Nasopharyngeal Carcinoma
Clinical utility of [68Ga]Ga-labeled fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography for primary staging and recurrence detection in nasopharyngeal carcinoma.
Neoplasm Metastasis
68Ga-FAPI-04 vs. 18F-FDG in a longitudinal preclinical PET imaging of metastatic breast cancer.
Dataset on FAP-induced emergence of spontaneous metastases and on the preparation of activatable FAP-targeting immunoliposomes to detect the metastases.
Fibroblast activation protein augments progression and metastasis of pancreatic ductal adenocarcinoma.
Fibroblast activation protein inhibitor (FAPi) positive tumour fraction on PET/CT correlates with Ki-67 in liver metastases of neuroendocrine tumours.
Fibroblast activation protein overexpression and clinical implications in solid tumors: a meta-analysis.
Fibroblast activation protein-positive fibroblasts promote tumor progression through secretion of CCL2 and interleukin-6 in esophageal squamous cell carcinoma.
Identification of inhibitory scFv antibodies targeting fibroblast activation protein utilizing phage display functional screens.
Immunization of stromal cell targeting fibroblast activation protein providing immunotherapy to breast cancer mouse model.
Potential of activatable FAP-targeting immunoliposomes in intraoperative imaging of spontaneous metastases.
Predictive values of FAP and HGF for tumor angiogenesis and metastasis in colorectal cancer.
Roles of Fibroblast Activation Protein and Hepatocyte Growth Factor Expressions in Angiogenesis and Metastasis of Gastric Cancer.
The Expression of Fibroblast Activation Protein in Clear Cell Renal Cell Carcinomas Is Associated with Synchronous Lymph Node Metastases.
Neoplasms
68Ga-FAPI-04 PET/CT Imaging for Fibrous Dysplasia of the Bone.
68Ga-FAPI-04 PET/MR is helpful in differential diagnosis of pancreatitis from pancreatic malignancy compared to 18F-FDG PET/CT: a case report.
68Ga-FAPI-04 Versus 18F-FDG PET/CT in the Detection of Hepatocellular Carcinoma.
68Ga-FAPI-04 vs. 18F-FDG in a longitudinal preclinical PET imaging of metastatic breast cancer.
68Ga-FAPI-PET/CT improves diagnostic staging and radiotherapy planning of adenoid cystic carcinomas - Imaging analysis and histological validation.
A case of nonfunctioning pancreatic endocrine tumor with atypical imaging findings due to prominent fibrosis of the tumor stroma.
A multi-antigen vaccine in combination with an immunotoxin targeting tumor-associated fibroblast for treating murine melanoma.
A new tumor vaccine: FAP?-MT elicits effective antitumor response by targeting Indolamine2, 3-dioxygenase in antigen presenting cells.
A novel antibody-4-1BBL fusion protein for targeted costimulation in cancer immunotherapy.
A novel role of dipeptidyl peptidase 9 in epidermal growth factor signaling.
A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.
A potent immunotoxin targeting fibroblast activation protein for treatment of breast cancer in mice.
A rare variant in human fibroblast activation protein associated with ER stress, loss of enzymatic function and loss of cell surface localisation.
A specific, transmembrane interface regulates fibroblast activation protein (FAP) homodimerization, trafficking and exopeptidase activity.
A synthetic urinary probe-coated nanoparticles sensitive to fibroblast activation protein ? for solid tumor diagnosis.
A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts.
A vaccine that co-targets tumor cells and cancer associated fibroblasts results in enhanced antitumor activity by inducing antigen spreading.
A whole-cell tumor vaccine modified to express fibroblast activation protein induces antitumor immunity against both tumor cells and cancer-associated fibroblasts.
Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth.
Activatable bispecific liposomes bearing fibroblast activation protein directed single chain fragment/Trastuzumab deliver encapsulated cargo into the nuclei of tumor cells and the tumor microenvironment simultaneously.
Activation of the A2B adenosine receptor in B16 melanomas induces CXCL12 expression in FAP-positive tumor stromal cells, enhancing tumor progression.
Activity of soluble OX40 ligand is enhanced by oligomerization and cell surface immobilization.
Ala657 and conserved active site residues promote fibroblast activation protein endopeptidase activity via distinct mechanisms of transition state stabilization.
Alteration of the Tumor Stroma Using a Consensus DNA Vaccine Targeting Fibroblast Activation Protein (FAP) Synergizes with Antitumor Vaccine Therapy in Mice.
An antibody fusion protein for cancer immunotherapy mimicking IL-15 trans-presentation at the tumor site.
Anti-tumor effects of DNA vaccine targeting human fibroblast activation protein ? by producing specific immune responses and altering tumor microenvironment in the 4T1 murine breast cancer model.
Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts.
Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein.
Author Correction: A whole-cell tumor vaccine modified to express fibroblast activation protein induces antitumor immunity against both tumor cells and cancer-associated fibroblasts.
Bispecific single-chain diabody-immunoliposomes targeting endoglin (CD105) and fibroblast activation protein (FAP) simultaneously.
Blockade of fibroblast activation protein in combination with radiation treatment in murine models of pancreatic adenocarcinoma.
Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model.
Cancer-associated fibroblasts downregulate type I interferon receptor to stimulate intratumoral stromagenesis.
Cancer-associated fibroblasts secrete hypoxia-induced serglycin to promote head and neck squamous cell carcinoma tumor cell growth in vitro and in vivo by activating the Wnt/?-catenin pathway.
Carboxypeptidase in prolyl oligopeptidase family: Unique enzyme activation and substrate-screening mechanisms.
CD117 expression in fibroblasts-like stromal cells indicates unfavorable clinical outcomes in ovarian carcinoma patients.
CD40 Agonist Targeted to Fibroblast Activation Protein ? Synergizes with Radiotherapy in Murine HPV-Positive Head and Neck Tumors.
Characterization and oncolytic virus targeting of FAP-expressing tumor-associated pericytes in glioblastoma.
Characterization of cancer stroma markers: in silico analysis of an mRNA expression database for fibroblast activation protein and endosialin.
Circulating concentrations of fibroblast activation protein ? in apparently healthy individuals and patients with acute coronary syndrome as assessed by sandwich ELISA.
Clinical implications of fibroblast activation protein in patients with colon cancer.
Clinical translational evaluation of Al18F-NOTA-FAPI for fibroblast activation protein-targeted tumour imaging.
Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8.
Comparisons of cancer-associated fibroblasts in the intratumoral stroma and invasive front in colorectal cancer.
Construction of a bispecific single chain antibody for recruitment of cytotoxic T cells to the tumour stroma associated antigen fibroblast activation protein.
Corrigendum: A whole-cell tumor vaccine modified to express fibroblast activation protein induces antitumor immunity against both tumor cells and cancer-associated fibroblasts.
COX/mPGES-1/PGE2 pathway depicts an inflammatory-dependent high-risk neuroblastoma subset.
Curcumin combined with FAP?c vaccine elicits effective antitumor response by targeting indolamine-2,3-dioxygenase and inhibiting EMT induced by TNF-? in melanoma.
Cyclophosphamide enhances anti-tumor effects of a fibroblast activation protein ?-based DNA vaccine in tumor-bearing mice with murine breast carcinoma.
Dataset on FAP-induced emergence of spontaneous metastases and on the preparation of activatable FAP-targeting immunoliposomes to detect the metastases.
Deletion of fibroblast activation protein provides atheroprotection.
Depletion of FAP+ cells reduces immunosuppressive cells and improves metabolism and functions CD8+T cells within tumors.
Design and validation of fibroblast activation protein alpha targeted imaging and therapeutic agents.
Development of novel FAP-targeted radiotracers with improved tumor retention.
Discovery of covalent prolyl oligopeptidase boronic ester inhibitors.
Distinct fibroblast functional states drive clinical outcomes in ovarian cancer and are regulated by TCF21.
Distribution of prolyl oligopeptidase in human peripheral tissues and body fluids.
Elevated 68Ga-FAPI Accumulation in a Recurrent Angiomyolipoma.
Elevated 68Ga-FAPI Activity in the Plasmacytoma of the Ribs.
Endothelial, pericyte and tumor cell expression in glioblastoma identifies fibroblast activation protein (FAP) as an excellent target for immunotherapy.
Enhancement of fibroblast activation protein ?-based vaccines and adenovirus boost immunity by cyclophosphamide through inhibiting IL-10 expression in 4T1 tumor bearing mice.
Evaluation of the circulating level of fibroblast activation protein ? for diagnosis of esophageal squamous cell carcinoma.
Expression and targeting of human fibroblast activation protein in a human skin/severe combined immunodeficient mouse breast cancer xenograft model.
Expression of anti-VEGF antibody together with anti-EGFR or anti-FAP enhances tumor regression as a result of vaccinia virotherapy.
Expression of fibroblast activation protein and the clinicopathological relevance in distal cholangiocarcinoma.
Expression of the FAP gene in non-fibroblast human cell lines. Development of cancer-associated fibroblast models.
Expression profiling of dipeptidyl peptidase 8 and 9 in breast and ovarian carcinoma cell lines.
Extracellular matrix directs phenotypic heterogeneity of activated fibroblasts.
FAPI PET/CT research progress in digestive system tumours.
FAPI PET/CT: Will It End the Hegemony of 18F-FDG in Oncology?
FAPI-PET/CT: biodistribution and preliminary dosimetry estimate of two DOTA-containing FAP-targeting agents in patients with various cancers.
Feasibility and Therapeutic Potential of 177Lu-Fibroblast Activation Protein Inhibitor-46 for Patients With Relapsed or Refractory Cancers: A Preliminary Study.
Feasibility, Biodistribution and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy (PTRT) of Diverse Adenocarcinomas using 177Lu-FAP-2286: First-in-Human Results.
Fibroblast Activation Protein (FAP) Overexpression Induces Epithelial-Mesenchymal Transition (EMT) in Oral Squamous Cell Carcinoma by Down-Regulating Dipeptidyl Peptidase 9 (DPP9).
Fibroblast Activation Protein (FAP) specific PET for advanced target volume delineation in glioblastoma.
Fibroblast Activation Protein (FAP)-Targeted CAR-T Cells: Launching an Attack on Tumor Stroma.
Fibroblast Activation Protein ?-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity.
Fibroblast activation protein alpha is expressed by transformed and stromal cells and is associated with mesenchymal features in glioblastoma.
Fibroblast activation protein and its prognostic significance in correlation with vascular endothelial growth factor in pancreatic adenocarcinoma.
Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma.
Fibroblast Activation Protein Expressing Mesenchymal Cells Promote Glioblastoma Angiogenesis.
Fibroblast activation protein in osteosarcoma cells promotes angiogenesis via AKT and ERK signaling pathways.
Fibroblast activation protein increases metastatic potential of fibrosarcoma line HT1080 through upregulation of integrin-mediated signaling pathways.
Fibroblast activation protein inhibitor (FAPi) positive tumour fraction on PET/CT correlates with Ki-67 in liver metastases of neuroendocrine tumours.
Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes.
Fibroblast activation protein is induced by inflammation and degrades type I collagen in thin-cap fibroatheromata.
Fibroblast activation protein overexpression and clinical implications in solid tumors: a meta-analysis.
Fibroblast activation protein predicts prognosis in clear cell renal cell carcinoma.
Fibroblast activation protein protects bortezomib-induced apoptosis in multiple myeloma cells through ?-catenin signaling pathway.
Fibroblast activation protein regulates lesion burden and the fibro-inflammatory response in Apoe-deficient mice in a sexually dimorphic manner.
Fibroblast activation protein restrains adipogenic differentiation and regulates matrix-mediated mTOR signaling.
Fibroblast activation protein targeted therapy using [177Lu]FAPI-46 compared with [225Ac]FAPI-46 in a pancreatic cancer model.
Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts.
Fibroblast activation protein, a potential diagnostic and therapeutic target for cancer.
Fibroblast activation protein-positive fibroblasts promote tumor progression through secretion of CCL2 and interleukin-6 in esophageal squamous cell carcinoma.
Fibroblast activation protein: A potential therapeutic target in cancer.
Fibroblast activation protein: differential expression and serine protease activity in reactive stromal fibroblasts of melanocytic skin tumors.
Fibroblast activation protein: purification, epitope mapping and induction by growth factors.
Fibrous Dysplasia Mimicking Skeletal Metastasis on 68Ga-FAPI PET Imaging.
Fusion of the tissue factor extracellular domain to a tumour stroma specific single-chain fragment variable antibody results in an antigen-specific coagulation-promoting molecule.
Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine.
Ga-68-FAPI as diagnostic tool in sarcoma: Data from the FAPI-PET prospective observational trial.
Generation of human high-affinity antibodies specific for the fibroblast activation protein by guided selection.
High Expression of FAP in Colorectal Cancer Is Associated With Angiogenesis and Immunoregulation Processes.
Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase-IV in human bone and soft tissue tumours.
Human antibody derivatives against the fibroblast activation protein for tumor stroma targeting of carcinomas.
Human telomerase reverse transcriptase (hTERT) promotes cancer invasion by modulating cathepsin D via early growth response (EGR)-1.
Identification of inhibitory scFv antibodies targeting fibroblast activation protein utilizing phage display functional screens.
IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT.
Imaging of Fibroblast Activation Protein in Cancer Xenografts Using Novel (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine-Based Small Molecules.
Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia.
Immunization of stromal cell targeting fibroblast activation protein providing immunotherapy to breast cancer mouse model.
Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model.
Impact of FAPI-PET/CT on Target Volume Definition in Radiation Therapy of Locally Recurrent Pancreatic Cancer.
Improved cancer detection in Waldeyer's tonsillar ring by 68Ga-FAPI PET/CT imaging.
Improvement of anti-tumor immunity of fibroblast activation protein ? based vaccines by combination with cyclophosphamide in a murine model of breast cancer.
Increased angiotensin II-induced hypertension and inflammatory cytokines in mice lacking angiotensin-converting enzyme N domain activity.
Increased expression of stemness markers and altered tumor stroma in hepatocellular carcinoma under TACE-induced hypoxia: A biopsy and resection matched study.
Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
Inhibitor-Decorated Polymer Conjugates Targeting Fibroblast Activation Protein.
Initial clinical experience with 90Y-FAPI-46 radioligand therapy for advanced stage solid tumors: a case series of nine patients.
Laser Capture Microdissection of Epithelial Cancers Guided by Antibodies Against Fibroblast Activation Protein and Endosialin.
MM-BMSCs induce naïve CD4+ T lymphocytes dysfunction through fibroblast activation protein ?.
Molecular recognition of fibroblast activation protein for diagnostic and therapeutic applications.
Mouse fibroblast activation protein: molecular cloning, alternative splicing and expression in the reactive stroma of epithelial cancers.
Nanoparticle formulation of mycophenolate mofetil achieves enhanced efficacy against hepatocellular carcinoma by targeting tumour-associated fibroblast.
Neuropeptide Y is a physiological substrate of fibroblast activation protein: Enzyme kinetics in blood plasma and expression of Y2R and Y5R in human liver cirrhosis and hepatocellular carcinoma.
Non-malignant findings of focal 68Ga-FAPI-04 uptake in pancreas.
One-pot and one-step automated radio-synthesis of [18F]AlF-FAPI-74 using a multi purpose synthesizer: a proof-of-concept experiment.
Overcoming stromal barriers to immuno-oncological responses via fibroblast activation protein-targeted therapy.
Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents.
Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)-activated prodrug in murine xenograft models of human cancer.
Phase II Trial of Single Agent Val-boroPro (Talabostat) Inhibiting Fibroblast Activation Protein in Patients with Metastatic Colorectal Cancer.
Photodynamic molecular beacon triggered by fibroblast activation protein on cancer-associated fibroblasts for diagnosis and treatment of epithelial cancers.
Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients.
Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics.
Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model.
Protumorigenic effects of Snail-expression fibroblasts on colon cancer cells.
PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism.
Quantitation of fibroblast activation protein (FAP)-specific protease activity in mouse, baboon and human fluids and organs.
Radioimmunotherapy of fibroblast activation protein positive tumors by rapidly internalizing antibodies.
Rapid fibroblast activation in mammalian cells induced by silicon nanowire arrays.
Rapid Target Binding and Cargo Release of Activatable Liposomes Bearing HER2 and FAP Single-Chain Antibody Fragments Reveal Potentials for Image-Guided Delivery to Tumors.
Rational Design, Pharmacomodulation, and Synthesis of [68Ga]Ga-Alb-FAPtp-01, a Selective Tumor-Associated Fibroblast Activation Protein Tracer for PET Imaging of Glioma.
Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy.
Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin.
Regulation of Fibroblast Activation Protein by Transforming Growth Factor Beta-1 in Glioblastoma Microenvironment.
Rhabdomyosarcoma Cells Produce Their Own Extracellular Matrix With Minimal Involvement of Cancer-Associated Fibroblasts: A Preliminary Study.
Selective Activation of Anticancer Chemotherapy by Cancer-Associated Fibroblasts in the Tumor Microenvironment.
Selective Homogeneous Assay for Circulating Endopeptidase Fibroblast Activation Protein (FAP).
Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold.
Sequential cancer immunotherapy: targeted activity of dimeric TNF and IL-8.
Short hairpin RNA targeting of fibroblast activation protein inhibits tumor growth and improves the tumor microenvironment in a mouse model.
Single-chain Fv immunoliposomes for the targeting of fibroblast activation protein-expressing tumor stromal cells.
Species-crossreactive scFv against the tumor stroma marker "fibroblast activation protein" selected by phage display from an immunized FAP-/- knock-out mouse.
Species-specific real-time RT-PCR analysis of expression of stromal cell genes in a tumor xenotransplantation model in mice.
Specific inhibition of fibroblast activation protein (FAP)-alpha prevents tumor progression in vitro.
State-of-the-art modalities in cardio-oncology: insight from a nuclear medicine approach.
Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer.
Stromal expression of fibroblast activation protein/seprase, a cell membrane serine proteinase and gelatinase, is associated with longer survival in patients with invasive ductal carcinoma of breast.
Structural revision of kynapcin-12 by total synthesis, and inhibitory activities against prolyl oligopeptidase and cancer cells.
Structure-activity relationship and biochemical evaluation of novel fibroblast activation protein and prolyl endopeptidase inhibitors with ?-ketoamide warheads.
Suppression of tumor growth in mice by rationally designed pseudopeptide inhibitors of fibroblast activation protein and prolyl oligopeptidase.
Targeted disruption of mouse fibroblast activation protein.
Targeted lipid-coated nanoparticles: Delivery of tumor necrosis factor-functionalized particles to tumor cells.
Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug.
Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators.
Targeting fibroblast activation protein in cancer - Prospects and caveats.
Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity.
Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice.
Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an 18F-labeled FAP Inhibitor.
Targeting inhibition of fibroblast activation protein-? and prolyl oligopeptidase activities on cells common to metastatic tumor microenvironments.
Targeting of activated fibroblasts for imaging and therapy.
Targeting of cancer?associated fibroblasts enhances the efficacy of cancer chemotherapy by regulating the tumor microenvironment.
Targeting the Tumor Microenvironment with Fluorescence-Activatable Bispecific Endoglin/Fibroblast Activation Protein Targeting Liposomes.
Targeting the tumor stroma as a novel treatment strategy for breast cancer: shifting from the neoplastic cell-centric to a stroma-centric paradigm.
Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake.
TGF-beta-induced fibroblast activation protein expression, fibroblast activation protein expression increases the proliferation, adhesion, and migration of HO-8910PM.
The application of prostate specific membrane antigen in CART?cell therapy for treatment of prostate carcinoma (Review).
The application of the fibroblast activation protein ?-targeted immunotherapy strategy.
The development and validation of a combined kinetic fluorometric activity assay for fibroblast activation protein alpha and prolyl oligopeptidase in plasma.
The effect of ALA-PDT on reversing the activation of cancer-associated fibroblasts in cutaneous squamous cell carcinoma.
The fibroblast surface markers FAP, anti-fibroblast, and FSP are expressed by cells of epithelial origin and may be altered during epithelial-to-mesenchymal transition.
The Latest Developments in Imaging of Fibroblast Activation Protein.
The road to integrative cancer therapies: emergence of a tumor-associated fibroblast protease as a potential therapeutic target in cancer.
The role of FAPI-PET/CT for patients with malignancies of the lower gastrointestinal tract - first clinical experience.
The role of fibroblast activation protein in health and malignancy.
Theranostics targeting fibroblast activation protein in the tumor stroma: 64Cu and 225Ac labelled FAPI-04 in pancreatic cancer xenograft mouse models.
Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells.
Tumor elastography and its association with cell-free tumor DNA in the plasma of breast tumor patients: a pilot study.
Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts.
Tumor-associated mesothelial cells are negative prognostic factors in gastric cancer and promote peritoneal dissemination of adherent gastric cancer cells by chemotaxis.
Tumor-specific crosslinking of GITR as costimulation for immunotherapy.
Ultrasensitive Fluorescent Probes Reveal an Adverse Action of Dipeptide Peptidase IV and Fibroblast Activation Protein during Proliferation of Cancer Cells.
Understanding fibroblast activation protein (FAP): Substrates, activities, expression and targeting for cancer therapy.
Using Substrate Specificity of Antiplasmin-cleaving Enzyme for Fibroblast Activation Protein Inhibitor Design.
UV radiation promotes melanoma dissemination mediated by the sequential reaction axis of cathepsins-TGF-?1-FAP-?.
Vaccine-induced CD8 T cells are redirected with peptide-MHC class I-IgG antibody fusion proteins to eliminate tumor cells in vivo.
[Oncology PET radiopharmaceuticals in clinic and research in 2020].
Nervous System Diseases
Brain Pharmacokinetics of Two Prolyl Oligopeptidase Inhibitors, JTP-4819 and KYP-2047, in the Rat.
Investigation of novel chemical scaffolds targeting prolyl oligopeptidase for neurological therapeutics.
Use of Umbrella Sampling to Calculate the Entrance/Exit Pathway for Z-Pro-Prolinal Inhibitor in Prolyl Oligopeptidase.
Neuroblastoma
A prolyl oligopeptidase inhibitor, Z-Pro-Prolinal, inhibits glyceraldehyde-3-phosphate dehydrogenase translocation and production of reactive oxygen species in CV1-P cells exposed to 6-hydroxydopamine.
COX/mPGES-1/PGE2 pathway depicts an inflammatory-dependent high-risk neuroblastoma subset.
Inhibition of prolylendopeptidase does not affect gamma-secretase processing of amyloid precursor protein in a human neuroblastoma cell line.
Prolyl oligopeptidase is a glyceraldehyde-3-phosphate dehydrogenase-binding protein that regulates genotoxic stress-induced cell death.
Prolyl oligopeptidase participates in cell cycle progression in a human neuroblastoma cell line.
Prolyl oligopeptidase participates in the cytosine arabinoside-induced nuclear translocation of glyceraldehyde 3-phosphate dehydrogenase in a human neuroblastoma cell line.
Neurodegenerative Diseases
Alteration of prolyl oligopeptidase and activated ?-2-macroglobulin in multiple sclerosis subtypes and in the clinically isolated syndrome.
Effect of prolyl endopeptidase inhibition on arginine-vasopressin and thyrotrophin-releasing hormone catabolism in the rat brain.
New tricks of prolyl oligopeptidase inhibitors - A common drug therapy for several neurodegenerative diseases.
Prolyl oligopeptidase inhibition activates autophagy via protein phosphatase 2A.
Prolyl Oligopeptidase: A Rising Star on the Stage of Neuroinflammation Research.
Purification, characterization and the use of recombinant prolyl oligopeptidase from Myxococcus xanthus for gluten hydrolysis.
Spatiotemporal expression and inhibition of prolyl oligopeptidase contradict its involvement in key pathologic mechanisms of kainic acid-induced temporal lobe epilepsy in rats.
Synthesis and biological evaluation of novel (123)I-labeled 4-(4-iodophenyl)butanoyl-L-prolyl-(2S)-pyrrolidines for imaging prolyl oligopeptidase in vivo.
Targeted Covalent Inhibition of Prolyl Oligopeptidase (POP): Discovery of Sulfonylfluoride Peptidomimetics.
The expression levels of prolyl oligopeptidase responds not only to neuroinflammation but also to systemic inflammation upon liver failure in rat models and cirrhotic patients.
Triosephosphate isomerase deficiency: consequences of an inherited mutation at mRNA, protein and metabolic levels.
Neuroendocrine Tumors
Fibroblast activation protein inhibitor (FAPi) positive tumour fraction on PET/CT correlates with Ki-67 in liver metastases of neuroendocrine tumours.
Neuroinflammatory Diseases
Deficiency of prolyl oligopeptidase in mice disturbs synaptic plasticity and reduces anxiety-like behaviour, body weight, and brain volume.
Prolyl Oligopeptidase: A Rising Star on the Stage of Neuroinflammation Research.
The expression levels of prolyl oligopeptidase responds not only to neuroinflammation but also to systemic inflammation upon liver failure in rat models and cirrhotic patients.
Non-alcoholic Fatty Liver Disease
Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity.
Obesity
Adipose tissue contribution to plasma fibroblast growth factor 21 and fibroblast activation protein in obesity.
Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity.
Obesity, Morbid
Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity.
Osteoporosis
Activity of dipeptidyl peptidase IV and post-proline cleaving enzyme in sera from osteoporotic patients.
Osteosarcoma
Fibroblast activation protein in osteosarcoma cells promotes angiogenesis via AKT and ERK signaling pathways.
Impact of fibroblast activation protein on osteosarcoma cell lines in vitro.
Overexpression of fibroblast activation protein and its clinical implications in patients with osteosarcoma.
The role of fibroblast activation protein in progression and development of osteosarcoma cells.
Ovarian Neoplasms
Distinct fibroblast functional states drive clinical outcomes in ovarian cancer and are regulated by TCF21.
High expression of fibroblast activation protein (FAP) predicts poor outcome in high-grade serous ovarian cancer.
Pancreatic Neoplasms
Fibroblast activation protein ?-positive pancreatic stellate cells promote the migration and invasion of pancreatic cancer by CXCL1-mediated Akt phosphorylation.
Fibroblast activation protein targeted therapy using [177Lu]FAPI-46 compared with [225Ac]FAPI-46 in a pancreatic cancer model.
The prolyl peptidases PRCP/PREP regulate IRS-1 stability critical for rapamycin-induced feedback activation of PI3K and AKT.
Theranostics targeting fibroblast activation protein in the tumor stroma: 64Cu and 225Ac labelled FAPI-04 in pancreatic cancer xenograft mouse models.
Paraproteinemias
Rhu-Epo down-regulates pro-tumorigenic activity of cancer-associated fibroblasts in multiple myeloma.
Parkinson Disease
A prolyl oligopeptidase inhibitor, KYP-2047, reduces ?-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease.
A single pathway targets several health challenges of the elderly.
Comparison of proline endopeptidase activity in brain tissue from normal cases and cases with Alzheimer's disease, Lewy body dementia, Parkinson's disease and Huntington's disease.
Computer-Aided Drug Discovery Identifies Alkaloid Inhibitors of Parkinson's Disease Associated Protein, Prolyl Oligopeptidase.
Discovery of covalent prolyl oligopeptidase boronic ester inhibitors.
Effects of the prolyl endopeptidase inhibitor S 17092 on cognitive deficits in chronic low dose MPTP-treated monkeys.
Inhibition of Prolyl Oligopeptidase Restores Spontaneous Motor Behavior in the ?-Synuclein Virus Vector-Based Parkinson's Disease Mouse Model by Decreasing ?-Synuclein Oligomeric Species in Mouse Brain.
Investigation of novel chemical scaffolds targeting prolyl oligopeptidase for neurological therapeutics.
Prolyl Endopeptidase-Like Facilitates the ?-Synuclein Aggregation Seeding, and This Effect Is Reverted by Serine Peptidase Inhibitor PMSF.
Prolyl oligopeptidase and dipeptidyl peptidase II/dipeptidyl peptidase IV ratio in the cerebrospinal fluid in Parkinson's disease: historical overview and future prospects.
Prolyl Oligopeptidase Enhances ?-Synuclein Dimerization via Direct Protein-Protein Interaction.
Removal of prolyl oligopeptidase reduces alpha-synuclein toxicity in cells and in vivo.
The effect of prolyl oligopeptidase inhibitors on alpha-synuclein aggregation and autophagy cannot be predicted by their inhibitory efficacy.
Periodontitis
Activity of dipeptidyl peptidase II and dipeptidyl peptidase IV in human gingiva with chronic marginal periodontitis.
Phyllodes Tumor
miR-21 induces myofibroblast differentiation and promotes the malignant progression of breast phyllodes tumors.
Plasmacytoma
Elevated 68Ga-FAPI Activity in the Plasmacytoma of the Ribs.
Prostatic Neoplasms
Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells.
Bee Venom Components as Therapeutic Tools against Prostate Cancer.
Pulmonary Fibrosis
Effects of the fibroblast activation protein inhibitor, PT100, in a murine model of pulmonary fibrosis.
Sarcoma
Fibroblast Activation Protein in Remodeling Tissues.
Fibroblast activation protein increases metastatic potential of fibrosarcoma line HT1080 through upregulation of integrin-mediated signaling pathways.
Ga-68-FAPI as diagnostic tool in sarcoma: Data from the FAPI-PET prospective observational trial.
Novel FAP ligands enable improved imaging contrast in sarcoma patients due to FAPI-PET/CT.
Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin.
Scleroderma, Systemic
Circulating fibroblast activation protein and dipeptidyl peptidase 4 in rheumatoid arthritis and systemic sclerosis.
Seizures
Pentylenetetrazol-induced seizures affect the levels of prolyl oligopeptidase, thimet oligopeptidase and glial proteins in rat brain regions, and attenuation by MK-801 pretreatment.
Squamous Cell Carcinoma of Head and Neck
Fibroblast Activation Protein (FAP) Overexpression Induces Epithelial-Mesenchymal Transition (EMT) in Oral Squamous Cell Carcinoma by Down-Regulating Dipeptidyl Peptidase 9 (DPP9).
Stomach Neoplasms
Activated gastric cancer-associated fibroblasts contribute to the malignant phenotype and 5-FU resistance via paracrine action in gastric cancer.
Effects of the fibroblast activation protein on the invasion and migration of gastric cancer.
Prolyl oligopeptidase inhibition-induced growth arrest of human gastric cancer cells.
Roles of Fibroblast Activation Protein and Hepatocyte Growth Factor Expressions in Angiogenesis and Metastasis of Gastric Cancer.
Roles of fibroblasts from the interface zone in invasion, migration, proliferation and apoptosis of gastric adenocarcinoma.
Synucleinopathies
P2-substituted N-acylprolylpyrrolidine inhibitors of prolyl oligopeptidase: biochemical evaluation, binding mode determination, and assessment in a cellular model of synucleinopathy.
Prolyl Oligopeptidase Enhances ?-Synuclein Dimerization via Direct Protein-Protein Interaction.
Thrombosis
Plasma levels of soluble fibroblast activation protein in arterial thrombosis: determinants and cleavage of its substrate alpha-2-antiplasmin.
Trypanosomiasis
Structure-function properties of prolyl oligopeptidase family enzymes.
The prolyl oligopeptidase family.
The Trypanosoma cruzi virulence factor oligopeptidase B (OPBTc) assembles into an active and stable dimer.
Tuberculosis
Mycobacterium tuberculosis puromycin hydrolase displays a prolyl oligopeptidase fold and an acyl aminopeptidase activity.
Significant accumulations of cathepsin B and prolylendopeptidase in inflammatory focus of delayed-type hypersensitivity induced by Mycobacterium tuberculosis in mice.
Ureteral Obstruction
Thymosin ?4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis.
Urinary Bladder Neoplasms
Stromal marker fibroblast activation protein drives outcome in T1 non-muscle invasive bladder cancer.
Vaccinia
Expression of anti-VEGF antibody together with anti-EGFR or anti-FAP enhances tumor regression as a result of vaccinia virotherapy.
Venous Insufficiency
The Inhibition of Prolyl Oligopeptidase as New Target to Counteract Chronic Venous Insufficiency: Findings in a Mouse Model.
Virus Diseases
Intrahepatic expression of collagen and fibroblast activation protein (FAP) in hepatitis C virus infection.
Intrahepatic expression of the hepatic stellate cell marker fibroblast activation protein correlates with the degree of fibrosis in hepatitis C virus infection.